Patisiran is a double-stranded synthetic oligonucleotide that improves neuropathy scores, 10-minute walk test results, NT-proBNP, and longitudinal LV strain levels and was approved in 2018 for ATTRh-associated peripheral neuropathy [20]. This evidence concerns the gene NPPB and neuropathy.